Cargando…

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016

Targeted therapies (TT) and immune checkpoint inhibitors (ICI) have become increasingly important in the treatment of metastatic malignant melanoma in recent years. We examined implementation and effectiveness of these new therapies over time in Germany with a focus on regional differences. We analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hellmund, Peter, Schmitt, Jochen, Roessler, Martin, Meier, Friedegund, Schoffer, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565277/ https://www.ncbi.nlm.nih.gov/pubmed/32825357 http://dx.doi.org/10.3390/cancers12092354

Ejemplares similares

Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020—Cohort Study Based on Administrative Data
por: Datzmann, Thomas, et al.
Publicado: (2021)

Ranking hospitals when performance and risk factors are correlated: A simulation-based comparison of risk adjustment approaches for binary outcomes
por: Roessler, Martin, et al.
Publicado: (2019)

Can we trust the standardized mortality ratio? A formal analysis and evaluation based on axiomatic requirements
por: Roessler, Martin, et al.
Publicado: (2021)

Exploring relationships between in-hospital mortality and hospital case volume using random forest: results of a cohort study based on a nationwide sample of German hospitals, 2016–2018
por: Roessler, Martin, et al.
Publicado: (2022)

Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
por: Kuske, Marvin, et al.
Publicado: (2018)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Relationships between multiple patient safety outcomes and healthcare and hospital-related risk factors in colorectal resection cases: cross-sectional evidence from a nationwide sample of 232 German hospitals
por: Walther, Felix, et al.
Publicado: (2022)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Effect of clinical peer review on mortality in patients ventilated for more than 24 hours: a cluster randomised controlled trial
por: Schmitt, Jochen, et al.
Publicado: (2023)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
por: Karlsson, Adam K, et al.
Publicado: (2017)

A Qualitative Needs Analysis of Skin Cancer Care from the Perspectives of Patients, Physicians, and Health Insurance Representatives—A Case Study from Eastern Saxony, Germany
por: Mathiebe, Josephine, et al.
Publicado: (2022)

Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
por: Schoffer, Olaf, et al.
Publicado: (2016)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Effectiveness of Global Treatment Budgets for Patients With Mental Disorders—Claims Data Based Meta-Analysis of 13 Controlled Studies From Germany
por: Baum, Fabian, et al.
Publicado: (2020)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina
por: Wohlmuth, Christoph, et al.
Publicado: (2020)

Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016)
por: Loya, Asad, et al.
Publicado: (2022)

6. Treatment resistant ulcerating dermatomyositis in metastatic melanoma treated with checkpoint inhibitor therapy
por: Parker, Lucy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h8mh0t4gfrb785r0mjma3s8o9v